Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program

Acta Oncologica

Volumn 47, Issue 2, 2008, Pages 225-231

  Hofvind, Solveig ^a,b   Sørum, Ragnhild ^a   Thoresen, Steinar ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASS SCREENING; METASTASIS; NORWAY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; NORWAY; PROGNOSIS; PROGRAM DEVELOPMENT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38349108519     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701518041     Document Type: Article

References (25)

1. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002;359:909-19.
2. Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 2005;330:220.
3. The Cancer Registry of Norway. Cancer in Norway, 2005. Oslo: The Cancer Registry of Norway; 2006.
4. Vainio H, Bianchini F, editors. IARC Handbook of Cancer Prevention Volume 7 Breast Cancer Screening. Lyon: IARCPress; 2002. http:/www.iarc.fr
5. Perry N, Broeders M, deWolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. European Communities, 2006. Printed in Belgium. http:/europa.eu.int
6. Hofvind S, Wang H, Thoresen S. Do the results of the process indicators in the Norwegian Breast Cancer Screening Program predict future mortality reduction from breast cancer? Acta Oncol 2004;43:467-73.
7. Hofvind S, Geller B, Vacek P, Thoresen S, Skaane P. Using the European Guidelines to evaluate the Norwegian Breast Cancer Screening Program. Euro J Epidemiol 2007 Jun 27.
8. The Ministry of Health and Social Affairs. Regulations on the collection and processing of personal health data in the Cancer Registry of Norway (Cancer Registry Regulations). Oslo: The Ministry of Health and Social Affairs; 2001.
9. Tabar L, Tot T, Dean P. Breast Cancer. The art of science of early detection with mammography. Stuttgart, New York: Georg Thieme Verlag; 2005. ISBN 3-13-135371-6 (GTV)
10. Hofvind S, Sorum R, Haldorsen T, Langmark F. Incidence of breast cancer before and after implementation of mammography screening. Tidsskr Nor Laegeforen 2006;126:2935-8.
11. Hofvind S, Moller B, Thoresen S, Ursin G. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 2006;118: 3112-7.
12. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2007.
13. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: Update of a randomised controlled study. Lancet Oncol 2006;7:983-90.
14. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: Prospective cohort study. BMJ 2004;328:921-4.
15. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: Follow-up study. BMJ 2006;332:689-92.
16. Hakama M, Holli K, Isola J, Kallioniemi OP, Karkkainen A, Visakorpi T, et al. Aggressiveness of screen-detected breast cancers. Lancet 1995;345:221-4.
17. Paci E, Miccinesi G, Puliti D, Baldazzi P, De L, V, Falcini F, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res 2006;8:R68.
18. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol 1995; 13:1144-51.
19. Michaelson JS, Satija S, Kopans D, Moore R, Silverstein M, Comegno A, et al. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. Cancer 2003;98:2114-24.
20. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581-6.
21. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-54.
22. Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HH, et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer 2003;39:1755-60.
23. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9.
24. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-4.
25. Zackrisson S, Andersson I, Manjer J, Janzon L. Non-attendance in breast cancer screening is associated with unfavourable socio-economic circumstances and advanced carcinoma. Int J Cancer 2004;108:754-60.